KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a key member of the RAS family. Mutations in KRAS are among the most common oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. It is estimated that KRAS mutations ...
Topic
KRAS-targeted therapy
Techniques for detecting, quantifying and localizing antigens and antibodies — ELISA, Western blotting, immunohistochemistry and flow cytometry. Below are the protocols, FAQs and technical articles in our knowledge base tagged with this topic.
2 resources · protocols, FAQs & articles
The KRAS G12C mutation is one of the common driver mutations in malignant tumors such as colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Recently approved KRAS G12C inhibitors like Adagrasib (MRTX849) and Sotorasib have provided unprecedented therapeutic options for patients.
Related topics
Techniques often explored alongside immunological experiments.